Preliminary data support the effect of Nitric Oxide (NO) on improving the oxygenation in mechanically ventilated patients and spontaneously breathing patients with COVID-19. In vitro studies showed an antiviral effect of NO against SARS-coronavirus. The optimal therapeutic regimen of NO gas in spontaneously breathing hypoxemic patients with COVID-19 is not known. We hypothesize that high concentration inhaled NO with an adjunct of continuous low dose administration between the high concentration treatments can be safely administered in hypoxemic COVID-19 patients compared to the high dose treatment alone. Prolonged administration of NO gas may benefit the patients in terms of the severity of the clinical course and time to recovery. Together with a clinical effect on ventilation-perfusion matching, a prolonged regimen would allow also an increase in antiviral activity (dose and time-dependent).

Start Date24 Jul 2020

Sponsor / Collaborator

Tomsk National Research Medical Center of the Russian Academy of Sciences

[+1]

NCT03855046 / RecruitingPhase 4IIT

A Comparative Efficacy and Safety Study of Lateral Subcutaneous Sphincterotomy and Botulinum Toxin Type A in the Treatment of Chronic Anal Fissure

This study is aimed at studying the efficacy and safety of treating chronic anal fissure with botulinum toxin versus lateral subcutaneous sphincterotomy.

Start Date01 Sep 2019

Sponsor / Collaborator

Pavlov First Saint Petersburg State Medical University

[+3]

ISRCTN10577372 / CompletedNot ApplicableIIT

Dose-finding and pharmacokinetic studies of praziquantel in patients infected with Opisthorchis felineus

Start Date01 Jun 2017

Sponsor / Collaborator

Siberian State Medical University

100 Clinical Results associated with Siberian State Medical University

0 Patents (Medical) associated with Siberian State Medical University

3,163

Literatures (Medical) associated with Siberian State Medical University

20 Sep 2024·Current Stem Cell Research & Therapy

The Acute Kidney Injury Induced by Cisplatin in Mice is Exacerbated by the Conditioned Medium Derived from the Cultivation of Mesenchymal Stem Cells under Hypoxic Conditions

Author: Dolbnya, Andrey D. ; Temnov, Andrey A. ; Pekov, Stanislav I. ; Popov, Igor A. ; Sklifas, Alla N. ; Klychnikova, Elena V. ; Sharapov, Mars G. ; Fadeev, Roman S.

Background:Acute Kidney Injury (AKI) is a severe complication of cisplatin-based chemotherapy. Thus, searching for novel therapeutic approaches to reduce system toxicity is vital for improving patient outcomes. The use of stem cells or the paracrine factors released by these cells during cultivation is currently being explored as a potential method for AKI prevention during chemotherapy. However, the conditions of stem cell cultivation considerably affect the composition of paracrine factors released by cells.Objective:In this study, we aimed to investigate the impact of paracrine factors derived from mesenchymal stem cells cultured under hypoxic conditions on the progression of AKI induced by cisplatin.Methods:AKI was induced in mice by intraperitoneal administration of cisplatin with the simultaneous injection of fractions of conditioned medium obtained from the cultivation of mesenchymal stem cells under hypoxic conditions. The survival rate of animals was assessed alongside qRTPCR implementation to assess gene expression of cytokines.Results:The total fraction of conditioned medium and >30 kDa fraction had no impact on cisplatin nephrotoxicity in mice. However, either subcutaneous or intraperitoneal administration of <30 kDa fraction of conditioned medium exacerbated animal mortality and led to severe damage to renal tissues. The effect was in a good correlation with KIM-1 and CDKN1A gene expression.Conclusion:The conditioned medium obtained during mesenchymal stem cells under hypoxic conditions has been found to markedly amplify the toxicity of cisplatin, which should be considered in stem cell therapy of AKI patients.

01 Sep 2024·Problems of Biological, Medical and Pharmaceutical Chemistry

ASSESSMENT OF ANTIOXIDANT, HYPOGLYCEMIC AND HYPOLYPIDEMIC ACTIVITIES OF THE HERBAL EXTRACT OF HILL-GROWING SALTWORT (SALSOLA COLLINA)

Author: Ivanov, A.A. ; Korotchenko, N.V. ; Burkova, V.N. ; Sergun, V.P. ; Samoylova, Yu.G.

Introduction. The development of safe and effective natural antioxidant drugs is an important task in the prevention and treatment of cardiovascular diseases, which are a serious public health problem. Work Objective is a study of the antioxidant, hypoglycemic and hypolipidemic activities of the herbal extract of hill-growing saltwort (Salsola collina) in comparison with the effect of a standard antioxidant agent. Material and methods. The object of the study was a "Hepatosol" biologically active food supplement based on a dry concentrated aqueous extract of the Salsola collina herb in capsules. The patients under observation were matched groups of obese women and men of comparable age with risk factors for cardiovascular diseases. Dur-ing the study, tolerability and possible adverse events were recorded and vital signs were monitored. The results of a biochemical blood test, lipid pro-file, oxidative stress and body composition analysis of patients were also evaluated and interpreted. Results. It has been found out that the parameters of the lipid profile and antioxidant status in patients with obesity and a risk of cardiovascular com-plications taking the herbal extract of hill-growing saltwort for 3 months returned to normal. A hypoglycemic positive effect of the herbal extract of hill-growing saltwort on reducing the body weight of patients has been recorded. The safety and good tolerability of the study drug have been confirmed. Conclusions. The results of studies show that a biologically active food supplement "Hepatosol" based on the extract of the Salsola collina herb has antioxidant, hypoglycemic and hypolipidemic activities. Due to these properties, the drugs based on a dry concentrated aqueous extract of the Salsola collina herb are favorable for diet therapy of patients with diabetes mellitus, for weight loss and use in the prevention and complex therapy of cardio-vascular diseases.

01 Sep 2024·Current Problems in Cardiology

Can Semaglutide offer hope for patients with obesity-related heart failure?

Review

Author: Ajayi, Joan Oluwadamilola ; Rao, Nitin Narayan ; Nebuwa, Chikodili ; Olanisa, Olawale ; Awoyinfa, Michael ; Olatunji, Gbolahan ; Ogieuhi, Ikponmwosa Jude ; Ajimotokan, Oluwafemi ; Napoleon, Tejiri ; Aderinto, Nicholas ; Samuel, Owolabi ; Kokori, Emmanuel ; Abraham, Israel Charles ; Ezeano, Chimezirim ; Temidayo, Ajayi Oluwatomisin

Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge with limited treatment options. This review explores the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, for HFpEF treatment. Studies suggest promising benefits, including symptom improvement, weight management, and the potential for enhanced exercise capacity. However, the evidence for semaglutide's impact on exercise capacity and heart function remains inconclusive, and its anti-inflammatory effects require further investigation. The safety profile appears favorable, with gastrointestinal side effects being the most common adverse events. It is crucial to emphasize that additional research with longer follow-up, head-to-head comparisons, and exploration of optimal dosage and mechanisms of action are necessary to solidify semaglutide's role in HFpEF treatment. Semaglutide is promising to improve symptoms, promote weight loss, and potentially influence underlying HFpEF mechanisms. Future research can refine treatment strategies and unlock the full potential of semaglutide for this patient population.

100 Deals associated with Siberian State Medical University

100 Translational Medicine associated with Siberian State Medical University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 20 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Meta-chlorobenzhydryl urea ( CYPs )	Epilepsy More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Siberian State Medical University

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 20 Dec 2024

Current Projects

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing